VEGFA and meningioma: The National Comprehensive Cancer Network (NCCN) guideline identified three drug classes that showed some benefits for treatment of meningioma in retrospective analysis or small phase II trials: vascular endothelial growth factor (VEGF) signaling pathway inhibitors, alpha-interferons, and somatostatin receptor agonists (6, 7).